0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Eltrombopag-Associated Hyperpigmentation FREE

Inbal Braunstein, MD1; Karolyn A. Wanat, MD1; Rosalie Elenitsas, MD1,2; XiaoWei Xu, MD, PhD1,2; Noelle Frey, MD3; Misha Rosenbach, MD1
[+] Author Affiliations
1Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
2Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia
3Department of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
JAMA Dermatol. 2013;149(9):1112-1115. doi:10.1001/jamadermatol.2013.5107.
Text Size: A A A
Published online

We report 2 cases of cutaneous hyperpigmentation with eltrombopag, a novel thrombopoietin receptor agonist.

REPORT OF CASES

Case 1

A 69-year-old white woman with refractory acute myelogenous leukemia (AML) was referred to dermatology for skin graying. Treatment with eltrombopag, 300 mg/d, was initiated in a clinical trial.1 After 3 months, the patient’s husband and clinical team noted gray hyperpigmentation predominantly affecting the face (Figure 1A). She had received cytarabine and daunorubicin 10 weeks prior to eltrombopag and sirolimus and mitoxantrone 5 weeks prior to eltrombopag. The hands, nails, sclera, and mucosa were uninvolved. Histopathologic examination of preauricular skin demonstrated mild inflammation and focal dermal pigment that stained positive with Fontana-Masson and weakly positive with Prussian blue (Figure 1B-D). The pigmentation remained stable over the subsequent 8 months during eltrombopag treatment.

Place holder to copy figure label and caption
Figure 1.
Images From Case 1

A, Clinical photograph of patient 1 demonstrates subtle gray discoloration of the face compared with the patient’s hands. B, Histopathologic image demonstrates brown granules of pigmentation (hematoxylin-eosin, original magnification ×600). C and D, This pigment was highlighted by Fontana-Masson stain (C) (original magnification ×600) and stained weakly positive with Prussian blue (D) (original magnification ×600).

Graphic Jump Location
Case 2

A 66-year-old woman of mixed white, African, and Native American descent with refractory AML developed darkening of her skin during treatment with eltrombopag. She had received cytarabine and daunorubicin 3 months prior to initiating a clinical trial with eltrombopag. Two months after starting eltrombopag therapy, the dermatology consult team was called to evaluate subcutaneous nodules clinically suggestive of Sweet syndrome. At that time she was noted to have a diffuse dusky complexion involving her face, arms, and legs. A biopsy of a subcutaneous nodule on her leg was performed. In addition to deep neutrophilic inflammation, there was prominent pigment deposition in the mid to deep dermis staining positive with both Fontana-Masson and Prussian blue stains (Figure 2). The pigmentation remained stable 3 months into eltrombopag therapy. The patient, her husband, and the oncology team believed that she was notably darker than before beginning eltrombopag treatment, and on comparison with a family photograph, the patient’s skin was believed to be darker than baseline by the dermatology team.

Place holder to copy figure label and caption
Figure 2.
Histopathologic Images From Case 2 With Diffuse Pigment Deposition

A, Low magnification demonstrates pigmentation throughout the dermis and in superficial subcutaneous tissue (hematoxylin-eosin, original magnification ×40). B-D, Higher magnification shows multiple foci of brown fine granules (B) (hematoxylin-eosin, original magnification ×600) that stain strongly positive with Fontana-Masson (C) (original magnification ×600) and Prussian blue (original magnification ×600).

Graphic Jump Location

DISCUSSION

Eltrombopag is a novel, nonpeptide thrombopoietin receptor agonist approved for treatment of chronic idiopathic thrombocytopenic purpura (ITP). It has also recently been approved for the treatment of hepatitis C associated thrombocytopenia2 and is currently being used in clinical trials for AML and myelodysplastic syndromes. Reported cutaneous adverse effects have been minimal. Pruritic exanthema have been reported in 3 patients taking eltrombopag, 25 to 50 mg/d, for ITP.3 In vitro studies suggest a theoretical phototoxic effect of eltrombopag; however, a clinical study of eltrombopag, 300 mg/d (75 mg 4 times daily) for 6 days, failed to show increased photosensitivity.4 To our knowledge, this is the first report of cutaneous hyperpigmentation associated with eltrombopag.

Numerous medications are associated with drug-induced hyperpigmentation, including minocycline, amiodarone, and chemotherapeutic agents including novel targeted therapies.5,6 The pathogenesis behind medication-associated hyperpigmentation remains unclear. Some attribute increased melanin deposition (measured by Fontana-Masson staining) to increased melanin production stimulated directly by the medication or indirectly by inflammation related to the medication. Likewise, hemosiderin deposition (seen with Prussian blue staining) is postulated to arise from red blood cell leakage (1) from direct vessel damage caused by the drug, (2) secondary to inflammation related to the drug or (3) due to deposition of specific pigments related to the drug.6

Although some of the other chemotherapeutic agents used previously in the patients have been associated with hyperpigmentation, the onset of the clinical graying in our patients occurred more than 10 weeks after discontinuing treatment with those agents. Additionally, the lack of inflammation or erythema in the skin, along with the presence of both hemosiderin and Fontana-Masson–positive material, supports a drug-associated hyperpigmentation rather than postinflammatory hyperpigmentation. The hyperpigmentation in case 1 appeared photodistributed, which, along with the superficial pigmentary deposits, may implicate phototoxic effects in the pathogenesis.

We describe the novel finding of cutaneous hyperpigmentation associated with eltrombopag and the associated pathologic findings. Further investigation is needed to better characterize this phenomenon.

ARTICLE INFORMATION

Corresponding Author: Inbal Braunstein, MD, 3600 Spruce St, 2 Maloney, Hospital of the University of Pennsylvania, Philadelphia, PA 19103 (inbal.braunstein@gmail.com).

Published Online: July 24, 2013. doi:10.1001/jamadermatol.2013.5107.

Conflict of Interest Disclosures: None reported.

Additional Contributions: We are indebted to Katie Dawson, MD, and the team from GlaxoSmithKline for helpful comments.

REFERENCES

Abramson Cancer Center of the University of Pennsylvania. A phase I/II study of eltrombopag in elderly patients with AML. http://www.clinicaltrials.gov/ct2/show/NCT01113502?term=eltrombopag+and+AML&rank=4. Accessed February 7, 2013.
Saleh  MN, Bussel  JB, Cheng  G,  et al; EXTEND Study Group.  Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537-545.
PubMed   |  Link to Article
Meyer  SC, Rovó  A, Tsakiris  DA, Scherer  K, Tichelli  A, Holbro  A.  Severe cutaneous toxicity related to eltrombopag. Br J Haematol. 2013;160(3):412-414.
PubMed   |  Link to Article
Bowen  CJ, Lobb  KM, Park  JW, Sanderson  B, Ferguson  J.  Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial. Photodermatol Photoimmunol Photomed. 2010;26(5):243-249.
PubMed   |  Link to Article
Susser  WS, Whitaker-Worth  DL, Grant-Kels  JM.  Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40(3):367-400.
PubMed   |  Link to Article
Dereure  O.  Drug-induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253-262.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.
Images From Case 1

A, Clinical photograph of patient 1 demonstrates subtle gray discoloration of the face compared with the patient’s hands. B, Histopathologic image demonstrates brown granules of pigmentation (hematoxylin-eosin, original magnification ×600). C and D, This pigment was highlighted by Fontana-Masson stain (C) (original magnification ×600) and stained weakly positive with Prussian blue (D) (original magnification ×600).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Histopathologic Images From Case 2 With Diffuse Pigment Deposition

A, Low magnification demonstrates pigmentation throughout the dermis and in superficial subcutaneous tissue (hematoxylin-eosin, original magnification ×40). B-D, Higher magnification shows multiple foci of brown fine granules (B) (hematoxylin-eosin, original magnification ×600) that stain strongly positive with Fontana-Masson (C) (original magnification ×600) and Prussian blue (original magnification ×600).

Graphic Jump Location

Tables

References

Abramson Cancer Center of the University of Pennsylvania. A phase I/II study of eltrombopag in elderly patients with AML. http://www.clinicaltrials.gov/ct2/show/NCT01113502?term=eltrombopag+and+AML&rank=4. Accessed February 7, 2013.
Saleh  MN, Bussel  JB, Cheng  G,  et al; EXTEND Study Group.  Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537-545.
PubMed   |  Link to Article
Meyer  SC, Rovó  A, Tsakiris  DA, Scherer  K, Tichelli  A, Holbro  A.  Severe cutaneous toxicity related to eltrombopag. Br J Haematol. 2013;160(3):412-414.
PubMed   |  Link to Article
Bowen  CJ, Lobb  KM, Park  JW, Sanderson  B, Ferguson  J.  Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial. Photodermatol Photoimmunol Photomed. 2010;26(5):243-249.
PubMed   |  Link to Article
Susser  WS, Whitaker-Worth  DL, Grant-Kels  JM.  Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40(3):367-400.
PubMed   |  Link to Article
Dereure  O.  Drug-induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253-262.
PubMed   |  Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles